Caribou Biosciences, Inc. · NASDAQ:CRBU
Caribou Biosciences — Corporate Update (May 2022)
19 slides from Caribou Biosciences's corporate update, May 12, 2022
Slide 1: CB-010 Clinical Program Update
Transformative genome-edited therapies for patients CB-010 Clinical Program Update May 12, 2022
Slide 2: Forward-looking statements
Forward-looking statements All statements in this presentation, other than statements of historical facts, are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements speak only as of the date of this presentation and a
Slide 3: CB-010: anti-CD19 allogeneic CAR-T cell therapy
CB-010: anti-CD19 allogeneic CAR-T cell therapy Key attributes CB-010 Conventional allo anti-CD19 CAR-Ts PD-1 KO for enhanced persistence of antitumor activity ✓ X Potentially better initial tumor debulking preclinically ✓ X Potentially better therapeutic index ✓ X Site-specific insertion of CAR int
Slide 4: Revolutionizing allogeneic cell therapies with CB-010: setting a new therapeutic bar
* 40x106 CAR-T cells ; † 80x106 CAR-T cells 1 All data as of Feb 23, 2022 data cutoff date, data collection ongoing, efficacy measured by Lugano criteria Source: Abstract for European Hematology Association (EHA) 2022 Hybrid Congress r/r B-NHL patients in ANTLER had aggressive disease (median 3 prio
Slide 5: Lead Program CB-010 ANTLER Phase 1 trial
LEAD PROGRAM CB-010 ANTLER Phase 1 trial
Slide 6: r/r B-NHL: high unmet need globally for off-the-shelf cell therapy
Worldwide NHL incidence2 B-NHL 5-year post-diagnosis survival rates3 1 National Cancer Institute, Leukemia & Lymphoma Society, Lymphoma Research Foundation 2 Evaluate Pharma, May 2022, www.evaluate.com 3 Cancer Research U.K. Diffuse large B cell lymphoma (DLBCL) Follicular lymphoma (FL) Marginal zon
Slide 7: CB-010 ANTLER Phase 1 trial design
CB-010 ANTLER Phase 1 trial design Patients with aggressive disease r/r B-NHL (DLBCL, HGBL, tFL, PMBCL, FL1, MZL2, MCL) ≥2 prior lines of chemoimmunotherapy Exclusion: prior CD19-targeted therapy DLT: dose-limiting toxicity ORR: objective response rate 1 Aggressively behaving, with POD24 (high risk)
Slide 8: ANTLER enrolled difficult-to-treat r/r B-NHL patients
ANTLER enrolled difficult-to-treat r/r B-NHL patients Patient characteristics Cohort 1 Dose level 1 (40x106 CAR-T cells) (N=6) Non-Hodgkin lymphoma subtype: DLBCL FL1 MCL PMBCL 2 2 1 1 Prior treatments Median number (range) 3 (2-8) ANTLER only enrolled patients with aggressive disease 1 Aggressively
Slide 9: CB-010 generally well tolerated at dose level 1
CB-010 generally well tolerated at dose level 1 No cases of graft versus host disease (GvHD) Most AEs were Grade 1 or Grade 2 No ≥Grade 2 CRS Single case of Grade 3 ICANS Case characterized as dose-limiting toxicity Patient received tocilizumab and steroids and recovered within 39 hours 28-day perio
Slide 10: CB-010: 1st allogeneic cell therapy to achieve 100% ORR
CB-010: 1st allogeneic cell therapy to achieve 100% ORR 6 patients treated with a single infusion at dose level 1 (40x106 CAR-T cells) 5 patients evaluable for efficacy at 28 days2 100% (n=5) ORR 80% (n=4) CR 20% (n=1) PR Of 4 patients who achieved a CR at 28 days2: All had ongoing CR at 3 months 6
Slide 11: Pipeline: initial focus on allogeneic cell therapy programs
Program Target Editing Indications Discovery IND enabling Phase 1 Phase 2 Phase 31 Anticipated milestone CAR-T platform with cell therapies for hematologic indications CB-010 CD19 CAR into TRAC; armoring: PD-1 KO r/r B-NHL initial data scheduled for EHA CB-011 BCMA CAR into TRAC; armoring: B2M KO, B
Slide 12: Initial ANTLER data validate Caribou's chRDNA genome-editing platform
Initial ANTLER data validate Caribou’s chRDNA genome-editing platform 100% ORR (80% CR) at 28 days1 from a single dose of CB-010 at dose level 1 (N=5) 1st allogeneic CAR-T cell therapy to achieve 100% ORR (5/5) Promising initial safety profile (N=6) Currently enrolling patients in ANTLER Phase 1 tri
Slide 13: With gratitude for patients, caregivers, investigators
With gratitude for patients, caregivers, investigators Clinicaltrials.gov NCT#04637763 MD Anderson Cancer Center, Houston Chao Family Comprehensive Cancer Center / University of California Irvine, Orange Oncology Hematology Care, Cincinnati Baylor Chares A. Sammons Cancer Center, Dallas HonorHealth,
Slide 14: Q&A
Q&A
Slide 15: See you at EHA in June!
See you at EHA in June! POSTER TITLE First-in-human trial of CB-010, a CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knock out, in patients with relapsed or refractory B cell non-Hodgkin lymphoma (ANTLER study) (Abstract P1455) DATE AND TIME Friday, June 10, 2022 16:30 – 17:45 CE
Slide 16: Appendix
Appendix
Slide 17: CB-010: an allogeneic cell therapy that may rival autologous anti-CD19 cell therapies
≥Grade 3 CRS, % CB-010 YESCARTA BREYANZI KYMRIAH none CB-010: an allogeneic cell therapy that may rival autologous anti-CD19 cell therapies EFFICACY SAFETY CB-010: 40x106 CAR-T cells YESCARTA: 2x106 CAR-T cells/kg BREYANZI: 50 to 110x106 CAR-T cells KYMRIAH: 2.5x108 CAR-T cells ORR CB-010 YESCARTA B
Slide 18: Deeper lymphodepletion protocol does not result in 100% ORR in B-NHL patients
Deeper lymphodepletion protocol does not result in 100% ORR in B-NHL patients B-NHL: B cell non-Hodgkin lymphoma Cy: cyclophosphamide Flu: fludarabine LD: lymphodepletion 1 Turtle CJ et al. Blood. 2015;126(23):184 LD regimen prior to autologous anti-CD19 CAR-T cell therapy infusion N= Objective resp
Slide 19: Thank you
https://cariboubio.com info@cariboubio.com Thank you